A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Tanke Biosciences Corp
TNBI
$210K
Mkt Cap
$0.02
+0.00%
Tanke Biosciences Corp (TNBI) has a 5-year average return on invested capital (ROIC) of 29.8%. This indicates strong capital allocation and a potential competitive advantage.
Tanke Biosciences Corp (TNBI) has a market capitalization of $266K. It is classified as a small-cap stock.
Tanke Biosciences Corp (TNBI) does not currently pay a regular dividend.
Tanke Biosciences Corp (TNBI) operates in the Grain Mill Products industry, within the Consumer Defensive sector.
Tanke Biosciences Corp (TNBI) reported annual revenue of $29 million in its most recent fiscal year, based on SEC EDGAR filings.
Tanke Biosciences Corp (TNBI) has a net profit margin of -0.7%. The company is currently unprofitable.
Tanke Biosciences Corp (TNBI) generated $-2 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Tanke Biosciences Corp operates in the Grain Mill Products industry, Consumer Defensive sector. Full business description from SEC filing not yet available.
| Segment | 201 | % of Total |
|---|---|---|
Organic Trace Mineral Additives | $25M | 83% |
Functional Regulation Additives | $4M | 14% |
Other | $1M | 2% |
Herbal Medicinal Additives | $0M | 1% |
| Metric | TTM | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|
| Revenue | 23M | 29M | 24M | 20M |
| Net Income | -1.6M | -210K | -3.1M | 2.7M |
| EPS | $-0.12 | $-0.02 | $-0.24 | $0.34 |
| Free Cash Flow | -6.3M | -2.0M | 3.0M | 4.3M |
| ROIC | -0.4% | 25.6% | 14.4% | 49.4% |
| Gross Margin | 32.3% | 34.8% | 36.8% | 36.8% |
| Debt/Equity | 0.12 | 0.13 | 0.09 | 0.17 |
| Dividends/Share | $0.00 | $0.00 | - | - |
| Operating Income | -57K | 4.5M | 1.7M | 4.4M |
| Operating Margin | -0.2% | 15.9% | 7.3% | 21.8% |
| ROE | -10.5% | -1.3% | -26.1% | 37.5% |
| Shares Outstanding | 13M | 11M | 13M | 8M |
| Metric | ||||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 20M | 24M | 29M | 23M |
| Gross Margin | 36.8% | 36.8% | 34.8% | 32.3% |
| R&D | N/A | 246K | 291K | 291K |
| SG&A | 835K | 4.5M | 2.6M | 4.1M |
| EBIT | 4.4M | 1.7M | 4.5M | -57K |
| Op. Margin | 21.8% | 7.3% | 15.9% | -0.2% |
| Net Income | 2.7M | -3.1M | -210K | -1.6M |
| Net Margin | 13.6% | -13.2% | -0.7% | -7.1% |
| Non-Recurring | 0 | 42K | 0 | 0 |
| Returns on Capital | ||||
| ROIC | 49.4% | 14.4% | 25.6% | -0.4% |
| ROE | 37.5% | -26.1% | -1.3% | -10.5% |
| ROA | 20.6% | -16.4% | -0.8% | -5.7% |
| Cash Flow | ||||
| Op. Cash Flow | 4.4M | 3.7M | -1.2M | -3.8M |
| Free Cash Flow | 4.3M | 3.0M | -2.0M | -6.3M |
| Owner Earnings | 4.2M | 761K | -2.3M | -6.3M |
| CapEx | 76K | 701K | 856K | 2.5M |
| Maint. CapEx | 136K | 400K | 636K | 862K |
| Growth CapEx | 0 | 301K | 220K | 1.6M |
| D&A | 136K | 400K | 636K | 862K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 0 | 2.5M | 494K | 1.6M |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -863K | -6.3M | -4.1M | -3.2M |
| Cash & Equiv. | 2.2M | 7.7M | 6.2M | 5.1M |
| Long-Term Debt | 453K | 628K | 793K | 733K |
| Debt/Equity | 0.17 | 0.09 | 0.13 | 0.12 |
| Interest Coverage | 43.6 | 1.3 | 3.1 | 3.1 |
| Equity | 8.2M | 16M | 16M | 16M |
| Total Assets | 13M | 25M | 29M | 29M |
| Total Liabilities | 2.9M | 9.0M | 13M | 13M |
| Intangibles | 287K | 838K | 1.2M | 1.1M |
| Retained Earnings | 5.8M | 2.7M | 2.5M | 1.6M |
| Working Capital | 5.3M | 15M | 10M | 7.5M |
| Current Assets | 7.7M | 19M | 22M | 20M |
| Current Liabilities | 2.4M | 3.5M | 12M | 12M |
| Per Share Data | ||||
| EPS | 0.34 | -0.24 | -0.02 | -0.12 |
| Owner EPS | 0.53 | 0.06 | -0.22 | -0.47 |
| Book Value | 1.01 | 1.21 | 1.50 | 1.17 |
| Cash Flow/Share | 0.54 | 0.28 | -0.11 | -0.06 |
| Dividends/Share | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 8.1M | 13.1M | 10.5M | 13.3M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -0.2 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 0.0 |
| Price/Sales | N/A | N/A | N/A | 0.0 |
| FCF Yield | N/A | N/A | N/A | -2353.1% |
| Market Cap | N/A | N/A | 0 | 266K |
| Avg. Price | N/A | N/A | 0.00 | 0.02 |
| Year-End Price | N/A | N/A | 0.00 | 0.02 |
Tanke Biosciences Corp passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 29.8% with a gross margin of 36.1%.
Tanke Biosciences Corp (TNBI) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
Tanke Biosciences Corp (TNBI) reported earnings per share (EPS) of $-0.02 in its most recent fiscal year.
Tanke Biosciences Corp (TNBI) has a return on equity (ROE) of -1.3%. A negative ROE may indicate losses or negative equity.
Tanke Biosciences Corp (TNBI) has a 5-year average gross margin of 36.1%. This indicates decent pricing power.
The Ledger Terminal provides 3 years of financial data for Tanke Biosciences Corp (TNBI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Tanke Biosciences Corp (TNBI) has a book value per share of $1.50, based on its most recent annual SEC filing.
No recent press releases.